Non-GMP DB-OTO lot B564TOXP1 used in all three GLP studies; clinical product manufactured under GMP. Bridging: Nonclinical material judged comparable to the clinical investigational product based on process consistency
“The nonclinical studies used non-GMP (Good Manufacturing Practice) material, while the clinical product is manufactured under GMP conditions. However, the nonclinical material was determined to be comparable to the clinical investigational drug product based on the process consistency. The same non-GMP lot (B564TOXP1) was used across all three GLP studies to ensure consistency in the pivotal safety and activity studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗
Genetically modified?
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Vector and route
Dual AAV1 vector system (hOTOF split into 5' and 3' halves), single intracochlear infusion
“The therapy utilizes a dual AAV1 vector system, in which the hOTOF gene is split into a 5' component and a 3' component, with each segment packaged into a separate AAV1 vector.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
First approval
2026 (FDA)
“Summary Basis for Regulatory Action Date: April 22, 2026”
✓ VerifiedFDA summary basis for approval, p. 1Source ↗
Several older rAd-IFN and Syn3NODA DS batches; not all representative of the clinical/commercial manufacturing process. Bridging: Quality data for some batches provided on request; considered supportive of the nonclinical profile
Several toxicology studies used a closely related predecessor product, AAVRh74var-Padua, similar to BEQVEZ. Bridging: Batches used in the pivotal nonclinical biodistribution and toxicity/genotoxicity testing considered representative of clinical batches
exagamglogene autotemcel · BCL11A enhancer (CRISPR-Cas9, ex vivo HSC)
Non-GMP lots from three healthy donors made with the same process and manufacturer as the GMP clinical material. Bridging: Toxicology lots were manufactured in a non-GMP facility using the same process and same manufacturer as for GMP material
Nonclinical material from Process A (Nationwide Children’s), Process B at ThermoFisher and Process B at Catalent. Bridging: Process A and Process B products not analytically comparable; commercial product is Process B (Catalent)
Definitive GLP safety and biodistribution studies and all clinical trials used FAYUVI manufactured under GMP conditions via Process A. Bridging: In vivo pharmacology studies bridged in vivo potency between the clinical Process A material and the later manufacturing process
Clinical vector DTX401 in toxicology studies; earlier vector versions encoding the same protein only in pharmacology Studies 1–4. Bridging: Titers from the initial assay converted to the final titer method by a conversion factor; doses reported as equivalents
Plasmid-derived AMT-010 batches and the baculovirus-derived commercial product AMT-011 both used in non-clinical studies. Bridging: AMT-011 qualified independently of AMT-010 on non-clinical data; toxicology and pharmacology studies were repeated with AMT-011
Programme initiated with predecessor AMT-060, same vector backbone but lacking the 2-nucleotide change giving the Padua FIX variant. Bridging: Predecessor and clinical vector showed a comparable safety profile when tested side-by-side in mice and NHPs
Process B (earlier process) material in toxicology studies; Phase III and commercial product made by Process C. Bridging: Comparability between batches from the different manufacturing processes demonstrated
Research grade lots scAAV9.CBA.SMN, OAV101 and OAV101B used in the nonclinical programme. Bridging: Among the research lots, OAV101B had specifications most comparable to the clinical product
Nonclinical studies used clinical lots 2004-101 and PBR-0045-001, not the intended commercial formulation. Bridging: Comparability of the clinical lots to lots made using the intended commercial process was provided
marnetegragene autotemcel · ITGB2 (LVV, ex vivo HSC)
Surrogate murine Lin- HSPCs transduced with the clinical vector used for the definitive in vivo toxicology and biodistribution studies. Bridging: All cells were transduced with the clinical vector, Chim-CD18-WPRE LV, which is used to produce RP-L201
Murine Lin- HSPCs from As2-/- mice and healthy human HSPCs transduced with ARSA LVV used for most nonclinical studies. Bridging: Remaining nonclinical studies used the clinical LVV, while some studies used vector versions with WPRE or an HA epitope tag
A precursor AAV2-hRPE65v2 vector product was used in normal-sighted dog studies at 1.5 x 1012 vg/eye. Bridging: Commercial lot shown comparable to the clinical material by lot release data and side-by-side comparability testing
One mouse study used a batch from early research process B, not representative of the commercial formulation; later studies used clinical-like lots. Bridging: Lots manufactured by the commercial process reported comparable to lots produced with earlier processes
elivaldogene autotemcel · ABCD1 (LVV, ex vivo HSC)
Healthy-donor CD34+ HSCs transduced with the same Lenti-D LVV used to produce the clinical product, not patient cells. Bridging: All cells were transduced with the same LVV, Lenti-D, that is used to produce eli-cel
autologous CD34+ cells transduced with ADA (no INN) · ADA (gamma-retroviral, ex vivo HSC)
CD34+ cells from healthy human umbilical cord blood transduced with the GSK3336223 vector, used instead of patient cells. Bridging: The test item was accepted as representative of Strimvelis
Clinical product TUDRIQEV in tumor-bearing mice; murine surrogate mRP1 in healthy rats. Bridging: Clinical-site and commercial-site (Framingham) batches compared in tumor-bearing mice; no differences in toxicology or biodistribution
Early-phase nonclinical studies used the early (Phase 1/2) production process; late-phase nonclinical studies used the Phase 3 process. Bridging: In vivo comparability study (KB103-IVV-010) in immunocompetent mice comparing batches from the two processes
Mouse surrogate: lineage-deficient HSPCs transduced with either the w1.6W or the clinical w1.6W_mut6 vector. Bridging: The clinical w1.6W_mut6 vector was used alongside the earlier w1.6W vector in both mouse models
The two 12-week GLP studies used process B material; all other safety studies used pre-process A batch material. Bridging: Current-process lots comparable to the initial clinical lot, including potency-to-vector-genome ratio and survival in a mouse SMA model
betibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
Surrogates: BB305 LVV-transduced thalassaemic mouse bone marrow cells or healthy human donor HSCs, not patient cells. Bridging: Surrogate test articles were transduced with BB305 LVV and administered to beta-thalassaemic and NSG mice